

**Guidelines for Deciding when to Disclose or Withhold Confidential Information**

*Intellectual Property (IP) is an asset that must be carefully managed and protected. At times, opportunities to patent or commercialise IP can be lost due to disclosure of confidential information. Disclosure includes but is not limited to publishing results before securing IP protection. To maximise the benefit from the commercialisation of IP, individuals should be aware of what constitutes confidential and non-confidential information.*

*In the table below are case examples of common situations where a researcher and/or commercialisation manager may need to assess the risk for disclosure, and a recommendation is given as to whether the information being considered is confidential or non-confidential information. These examples act as a guide and can be applied to various situations.*

Scenario	Non-Confidential Information	Confidential Information
I did a 5 year trial of my drug	X	
The results of the 5 year trial indicate that we should persist with the work	X	
The results of the 5 year trial were really encouraging and positive		X
The actual results of a 5 year trial of my drug were 6 people improved, 1 didn't etc.....		X
Additional information relating to my technology may be found in the published patent application at the USPTO website	X	
A copy of my unpublished patent application is attached		X
The invention in my unpublished patent shows how x can be used to give a y result		X
My most recent findings were published last year and I've attached a copy of the article for your review	X	
My latest unpublished data is / or shows that $x + y = z$		X
This technology may have additional applications not previously indicated/found and not defined in the Technology Investment Brief or the published patent application	X	
We have identified additional applications of our technology and these are.....		X
We intend to further develop our technology in areas that are new applications of the technology and in areas where other technologies are currently deficient	X	
We intend to develop our technology further by...		X
We have completed Phase 1 trials of our drug	X	
We have completed Phase 1 trials of our drug and our developmental strategy will be.... and the costs of further development will be ...		X